<DOC>
	<DOCNO>NCT02752893</DOCNO>
	<brief_summary>The investigator establish platform Dartmouth-Hitchcock Medical Center generate novel model estrogen receptor alpha-positive ( ER+ ) , human epidermal growth factor receptor 2-negative ( HER2- ) breast cancer , use research study develop novel treatment strategy dissect signal pathway underlie drug sensitivity resistance .</brief_summary>
	<brief_title>Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Inclusion criterion 1 . Men woman &gt; age 18 histologically document ER+/HER2 breast cancer history ER+/HER2 breast cancer , tumor biopsy surgical resection clinically indicate performed standard care . Tumor specimens may breast ( primary/recurrent ) metastatic site . Patients multicentric bilateral disease eligible . 2 . ER positivity define &gt; 10 % malignant tumor cell stain positively ER immunohistochemistry ( IHC ) . HER2 negativity define IHC 01+ , fluorescence situ hybridization ( FISH ) ratio &lt; 1.8 IHC 2+ IHC do . 3 . Excess LIVE tumor tissue must available surgically resect tumor specimen , 13 extra core needle incisional biopsy . LIVE tumor tissue must available within 2 hour removal patient ( short time preferable ) . 4 . A primary breast cancer must great 1 cm great diameter . 5 . Prior therapy allow long excess viable tumor tissue available biopsy surgical excision procedure . 6 . Ability give sign informed consent . Exclusion Criteria 1 . Fine needle aspirate effusion bodily fluid eligible source tumor cell .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>estrogen</keyword>
	<keyword>estrogen receptor</keyword>
	<keyword>ER+</keyword>
	<keyword>HER2</keyword>
	<keyword>HER2-</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>xenograft</keyword>
	<keyword>co-clinical</keyword>
	<keyword>mouse</keyword>
	<keyword>patient-derived xenograft</keyword>
	<keyword>patient-derived</keyword>
	<keyword>breast cancer</keyword>
	<keyword>precision medicine</keyword>
	<keyword>personalize medicine</keyword>
</DOC>